This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Health Policy  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2006;295:377.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Kathleen Uhl, MD, has been selected as the director of the Office of Women's Health of the Food and Drug Administration (FDA). Her appointment followed the August 31 departure of her predecessor, Susan Wood, PhD, who resigned to protest the FDA's announcement that it would delay a decision on allowing over-the-counter sales of the "morning-after" emergency contraceptive, Plan B. Wood said she could "no longer serve as staff when scientific and clinical evidence, fully evaluated and recommended for approval by the professional staff here, has been overruled."

Kathleen Uhl, MD, has been selected as the director of the Food and Drug Administration's Office of Women's Health. (Photo credit: Catherine Brown/FDA)

Uhl has worked at the FDA since 1998, most recently as a reviewer and supervisory medical officer in the Center for Drug Evaluation and Research's Pregnancy and Lactation Labeling Team in the Office of New Drugs. She . . . [Full Text of this Article]